AR066204A1 - Inmunoglobulina transcitotica - Google Patents

Inmunoglobulina transcitotica

Info

Publication number
AR066204A1
AR066204A1 ARP080101292A AR066204A1 AR 066204 A1 AR066204 A1 AR 066204A1 AR P080101292 A ARP080101292 A AR P080101292A AR 066204 A1 AR066204 A1 AR 066204A1
Authority
AR
Argentina
Prior art keywords
molecule
transport protein
modular
epitope
structural loop
Prior art date
Application number
Other languages
English (en)
Inventor
Gottfried Himmler
Gerda Redl
Original Assignee
F Star Biotech Forsch & Entw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Biotech Forsch & Entw filed Critical F Star Biotech Forsch & Entw
Publication of AR066204A1 publication Critical patent/AR066204A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método de produccion de un anticuerpo modular transcitotico que contiene un sitio de union sintético para una proteína de transporte mediante el desarrollo de una molécula que contiene un dominio de anticuerpo con el fin de modificar un bucle estructural y determinar la union de dicha molécula a un epitopo de una proteína de transporte, en el cual la molécula sin modificar no se une significativamente a dicha proteína de transporte, caracterizado porque comprende los pasos de: proveer un ácido nucleico que codifica una molécula la cual contiene un dominio de anticuerpo que comprende al menos una region de bucle estructural; modificar al menos un residuo de nucleotido de por lo menos una de dichas regiones de bucle estructural, poner en contacto la molécula modificada con un epitopo de una proteína de transporte, y determinar si dicha molécula modificada se une a dicho epitopo en un ensayo de transcitosis celular. Además un anticuerpo modular transcitotico producido de este modo, bibliotecas que contienen tales anticuerpos modulares, y un método de prolongacion de la vida promedio de anticuerpos modulares y moléculas biologicamente activas.
ARP080101292 2007-03-30 2008-03-28 Inmunoglobulina transcitotica AR066204A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07450065A EP1975178A1 (en) 2007-03-30 2007-03-30 Transcytotic modular antibody

Publications (1)

Publication Number Publication Date
AR066204A1 true AR066204A1 (es) 2009-08-05

Family

ID=38749489

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101292 AR066204A1 (es) 2007-03-30 2008-03-28 Inmunoglobulina transcitotica

Country Status (3)

Country Link
EP (1) EP1975178A1 (es)
AR (1) AR066204A1 (es)
WO (1) WO2008119096A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
WO2009000006A1 (en) 2007-06-26 2008-12-31 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Display of binding agents
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
CA2810668A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
WO2012044831A1 (en) * 2010-09-30 2012-04-05 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
BR112013013083A2 (pt) 2010-11-30 2016-12-13 Genentech Inc métodos para transportar um composto, para aumentar exposição do cns a um composto, para diminuir a depuração de um composto, para aumentar a retenção no cns de um composto, para otimizar a farmacocinética, para tratar um distúrbio neurológico em um mamífero, para desenvolver um anticorpo, anticorpo, fragmento de anticorpo, anticorpo multiespecífico e uso de um anticorpo
CN103502273A (zh) * 2011-04-20 2014-01-08 罗氏格黎卡特股份公司 用于pH依赖性通过血脑屏障的方法和构建体
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN104302665B (zh) * 2011-12-21 2019-04-23 安姆根有限公司 与新生儿Fc受体的结合增强的变体Fc多肽
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
EA037065B1 (ru) 2014-11-26 2021-02-01 Ксенкор, Инк. Гетеродимерные антитела, связывающие cd3 и cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
TN2017000223A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
JP7021127B2 (ja) 2016-06-28 2022-02-16 ゼンコア インコーポレイテッド ソマトスタチン受容体２に結合するヘテロ二量体抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2017342560B2 (en) 2016-10-14 2022-03-17 Xencor, Inc. IL15/IL15Ralpha heterodimeric Fc-fusion proteins
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
EP3837545A1 (en) * 2018-08-17 2021-06-23 F. Hoffmann-La Roche AG In vitro transcytosis assay
JP2022503959A (ja) 2018-10-03 2022-01-12 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
KR20220054585A (ko) * 2019-08-02 2022-05-03 얀센 바이오테크 인코포레이티드 고분자 항체 수용체 표적화를 위한 재료 및 방법
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
AU2022232375A1 (en) 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) * 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
CA2362373A1 (en) * 1999-02-12 2000-08-17 J. Donald Capra Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor
JP4652414B2 (ja) * 2004-11-12 2011-03-16 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
CA2594356C (en) * 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
US20100104564A1 (en) * 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
ES2523666T3 (es) * 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos

Also Published As

Publication number Publication date
WO2008119096A1 (en) 2008-10-09
EP1975178A1 (en) 2008-10-01

Similar Documents

Publication Publication Date Title
AR066204A1 (es) Inmunoglobulina transcitotica
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
EA201100527A1 (ru) Биологические продукты
HRP20090228T1 (en) Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
ES2560532T3 (es) Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
AR111361A1 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
TR201910213T4 (tr) Disülfürle stabilize edilmiş çok değerlikli antikorlar.
DE602005022830D1 (de) Weniger immunogene bindungsmoleküle
CY1113400T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
EP2535351A3 (en) Dual specificity antibody fusions
ATE534667T1 (de) Anti-abeta antikörper
BRPI0820885B8 (pt) "anticorpo ou fraguimento do mesmo, célula de hibridoma, polinucleotídeo, polipeptídeo compreendendoum domínio de cadeia pesada ou leve de anticorpo, método para detecção de gravidez em um animal bovino, kit e método de purificação de um antígeno principal associado à gravidez (pag)".
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
RS52804B (en) HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND THEIR USE
PE20090722A1 (es) Hepcidina, antagonistas de la hepcidina y metodos de uso
EA200700751A1 (ru) Способы и композиции для улучшения продуцирования рекомбинантного белка
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
DE60222816D1 (de) Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung
DE60014124D1 (de) Antikörper, die spezifisch für fullerene sind
WO2007001895A3 (en) Monoclonal antibodies, hybridoma cell lines, methods and kits for detecting phytase
CO6382184A2 (es) Proteinas fijadoras de receptores de interleukinas-21
PE20232050A1 (es) Anticuerpos anti-cd19 y estructuras car-t
WO2006075142A3 (en) FORMS OF FACTOR XIIa
DK1711531T3 (da) Neutraliserende anti-TLR4/-MD-2-antistoffer og fremgangsmåder til anvendelse deraf

Legal Events

Date Code Title Description
FB Suspension of granting procedure